论文部分内容阅读
目的观察伊立替康联合亚叶酸钙及氟尿嘧啶(FOLFIRI)一线治疗晚期胃癌的疗效、中位无进展生存时间(PFS)、总的生存时间(OS)及毒副作用。方法50例经过组织学证实的晚期胃癌患者接受FOLFIRI方案治疗,主要终点是:客观有效率(RR)、PFS、总生存时间(OS)及毒副反应。结果50例患者均可以接受疗效及生存评价,其中部分缓解(PR)23例(46.0%),稳定(SD)13例(26.0%),进展(PD)14例(28%),无CR病例。RR为46.0%,中位PFS时间为6.4个月,中位OS为10.6个月。结论FOLFIRI方案一线治疗局部晚期和转移性晚期胃癌能够提高RR、PFS及OS,副作用轻,耐受性好,可在临床推广应用。
Objective To observe the efficacy, median progression-free survival (PFS), total survival time (OS) and side effects of irinotecan combined with calcium folinate and fluorouracil (FOLFIRI) in the treatment of advanced gastric cancer. Methods Fifty patients with advanced gastric cancer who had been confirmed by histology were treated with FOLFIRI. The primary endpoints were: objective effectiveness (RR), PFS, overall survival time (OS), and toxic and side effects. Results All the 50 patients were eligible for efficacy and survival evaluation. Among them, 23 (46.0%) were partially relieved (PR), 13 (26.0%) were stable (SD), 14 (28%) were progressive (PD), and no CR was found. . The RR was 46.0%, the median PFS time was 6.4 months, and the median OS was 10.6 months. Conclusion FOLFIRI first-line treatment of locally advanced and metastatic advanced gastric cancer can improve RR, PFS and OS, with mild side effects and good tolerability. It can be widely used in clinic.